Clinical Trial Update: R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating tipifarnib (R115777) for progressive, metastatic prostate cancer that has not responded to hormone therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ZARNESTRA

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED